Illustration: Victoria Ellis/Axios
Crescent Capital is the lead lender for THL's $600 million buyout of Headlands Research, a source familiar tells Axios.
Why it matters: Despite broader challenges closing deals, investor and lender appetite for pharma services businesses remains strong.
